TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alvotech ( (ALVO) ) has shared an announcement.
On November 10, 2025, Alvotech announced that the UK High Court ruled in its favor, rejecting an injunction request from Regeneron Pharmaceuticals and Bayer. This decision allows Alvotech to continue manufacturing its biosimilar to Eylea (AVT06) in the UK, paving the way for its commercial launch in the European Economic Area and other regions after the expiry of the Supplementary Protection Certificates for Eylea on November 23, 2025. The ruling supports Alvotech’s strategy to enhance access to biosimilars and strengthen its position in the global biosimilar market.
The most recent analyst rating on (ALVO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score reflects a combination of improving profitability and positive earnings call sentiment, offset by significant financial risks and bearish technical indicators. The company’s strategic growth initiatives and strong product performance are promising, but challenges in revenue growth and market dynamics pose risks.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company specializing in the development and manufacture of biosimilar medicines. Founded by Robert Wessman, the company aims to be a leader in the biosimilar space by providing high-quality, cost-effective products. Alvotech has a broad pipeline of biosimilar candidates targeting various conditions, including autoimmune disorders and cancer, and has formed strategic partnerships to expand its market reach globally.
Average Trading Volume: 527,992
Technical Sentiment Signal: Sell
Current Market Cap: $1.65B
Learn more about ALVO stock on TipRanks’ Stock Analysis page.